- Home
- EXAS vs EVR Comparison
EXAS vs EVR Comparison
Compare EXAS & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- EVR
- Stock Information
- Founded
- EXAS 1995
- EVR 1995
- Country
- EXAS United States
- EVR United States
- Employees
- EXAS N/A
- EVR N/A
- Industry
- EXAS Medical Specialities
- EVR Investment Managers
- Sector
- EXAS Health Care
- EVR Finance
- Exchange
- EXAS Nasdaq
- EVR Nasdaq
- Market Cap
- EXAS 10.5B
- EVR 10.8B
- IPO Year
- EXAS N/A
- EVR 2006
- Fundamental
- Price
- EXAS $49.26
- EVR $250.06
- Analyst Decision
- EXAS Strong Buy
- EVR Hold
- Analyst Count
- EXAS 17
- EVR 6
- Target Price
- EXAS $72.31
- EVR $293.60
- AVG Volume (30 Days)
- EXAS 1.9M
- EVR 426.1K
- Earning Date
- EXAS 02-19-2025
- EVR 02-05-2025
- Dividend Yield
- EXAS N/A
- EVR 1.31%
- EPS Growth
- EXAS N/A
- EVR 42.54
- EPS
- EXAS N/A
- EVR 9.08
- Revenue
- EXAS $2,758,867,000.00
- EVR $2,979,593,000.00
- Revenue This Year
- EXAS $12.09
- EVR $23.91
- Revenue Next Year
- EXAS $11.24
- EVR $16.96
- P/E Ratio
- EXAS N/A
- EVR $26.89
- Revenue Growth
- EXAS 10.37
- EVR 22.82
- 52 Week Low
- EXAS $40.62
- EVR $175.24
- 52 Week High
- EXAS $79.62
- EVR $324.06
- Technical
- Relative Strength Index (RSI)
- EXAS 33.51
- EVR 29.92
- Support Level
- EXAS $45.94
- EVR $259.93
- Resistance Level
- EXAS $51.75
- EVR $275.69
- Average True Range (ATR)
- EXAS 2.13
- EVR 8.54
- MACD
- EXAS -0.30
- EVR -2.51
- Stochastic Oscillator
- EXAS 32.20
- EVR 10.92
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About EVR Evercore Inc.
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,200 employees at the end of 2023, and about 75% of its revenue is derived from the United States.